Lucida Clinical Trials is pleased to announce the upcoming launch of complimentary in-office FibroScan® assessments at our New Bedford and Braintree locations, beginning in April. This non-invasive technology enables rapid, reliable evaluation of liver stiffness and steatosis, supporting early identification and monitoring of patients with suspected or confirmed liver disease, including NASH.
By integrating FibroScan® into our site capabilities, Lucida strengthens its ability to efficiently identify, stratify, and enroll appropriate patients for liver-focused clinical trials. This added infrastructure enhances both feasibility and data quality for sponsors seeking experienced sites with advanced diagnostic tools readily available on-site.
We look forward to leveraging this capability to support ongoing and future NASH studies while improving access to cutting-edge liver health assessments for our patient community.
